Evaluating the Clinical and Economic Outcomes Associated with Poor Glycemic Control in People with Type 1 Diabetes in the Netherlands

References

• International Diabetes Federation. Diabetes Atlas – 10th Edition; 2021. Available from: https://diabetesatlas.org/data/en/. Accessed August 24, 2022.
   Google Scholar
• Volksgezondheidenzorg.info. Prevalentie diabetes in huisartsenpraktijk naar leeftijd en geslacht [Prevalence of diabetes in general practice by age and gender]; 2020. Available from: https://www.volksgezondheidenzorg.info/onderwerp/diabetes-mellitus/cijfers-context/huidige-situatie#node-prevalentie-diabetes-huisartsenpraktijk-naar-leeftijd-en-geslacht. Accessed August 24, 2022.
   Google Scholar
• Peters ML, Huisman EL, Schoonen M, Wolffenbuttel BHR. The current total economic burden of diabetes mellitus in the Netherlands. Neth J Med. 2017;75(7):281–297.
   PubMed Web of Science ®Google Scholar
• Liaropoulos L, Goranitis I. Health care financing and the sustainability of health systems. Int J Equity Health. 2015;14:80. doi:10.1186/s12939-015-0208-5
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. doi:10.1056/NEJM199309303291401
   PubMed Web of Science ®Google Scholar
• Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9–16. doi:10.2337/dc13-2112
   PubMed Web of Science ®Google Scholar
• The DCCT/EDIC Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up NIH external link. Diabetes Care. 2016;39(5):686–693. doi:10.2337/dc15-1990
   PubMed Web of Science ®Google Scholar
• Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152(1):27–38. doi:10.1016/j.ahj.2005.09.015
   PubMed Web of Science ®Google Scholar
• Smith A, Harris C. Type 1 diabetes: management strategies. Am Fam Physician. 2018;98(3):154–162.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 6. glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66–S76.
   PubMed Web of Science ®Google Scholar
• McKnight JA, Wild SH, Lamb MJE, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med. 2015;32(8):1036–1050. doi:10.1111/dme.12676
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Frier BM. Hypoglycaemia, the most feared complication of insulin therapy. Diabete Metab. 1994;20(6):503–512.
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Frier BM, Deary IJ. Appraisal of mood and personality during hypoglycaemia in human subjects. Physiol Behav. 1999;67(1):27–33. doi:10.1016/S0031-9384(99)00035-9
   PubMed Web of Science ®Google Scholar
• McCrimmon RJ, Sherwin RS. Hypoglycemia in Type 1 Diabetes. Diabetes. 2010;59(10):2333–2339. doi:10.2337/db10-0103
   PubMed Web of Science ®Google Scholar
• Bain SC, Bekker Hansen B, Hunt B, Chubb B, Valentine WJ. Evaluating the burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the UK. J Med Econ. 2020;23(1):98–105. doi:10.1080/13696998.2019.1645018
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5–26. doi:10.1185/030079904X1980
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27–40. doi:10.1185/030079904X2006
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17:14–24. doi:10.1016/j.jval.2014.07.007
   Web of Science ®Google Scholar
• World Health Organization. Global health observatory data repository: life tables by country (Netherlands); 2020. Available from: http://apps.who.int/gho/data/view.main.61160?lang=en. Accessed August 24, 2021.
   Google Scholar
• Zorginstituut Nederland. Guideline for economic evaluations in healthcare; 2016. Available from: https://english.zorginstituutnederland.nl/publications/reports/2016/06/16/guideline-for-economic-evaluations-in-healthcare. Accessed August 24, 2022.
   Google Scholar
• van Dijk PR, Pasch A, van Ockenburg-Brunet SL, et al. Thiols as markers of redox status in type 1 diabetes mellitus. Ther Adv Endocrinol Metab. 2020;11:2042018820903641. doi:10.1177/2042018820903641
   Web of Science ®Google Scholar
• Special Eurobarometer. Attitudes of Europeans towards tobacco and electronic cigarettes; 2017. Available from: https://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/ResultDoc/download/DocumentKy/79002. Accessed August 24, 2022.
   Google Scholar
• World Health Organization. Global status report on alcohol and health; 2018. Available from: http://apps.who.int/iris/bitstream/handle/10665/274603/9789241565639-eng.pdf?ua=1. Accessed August 24, 2022.
   Google Scholar
• Statistics Netherlands. Background migration data; 2022. Available from: https://www.cbs.nl/nl-nl/cijfers/detail/37325. Accessed August 24, 2022.
   Google Scholar
• Sørensen J, Ploug UJ. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Re Int. 2013;2013:618039.
   Google Scholar
• de Groot S, Enters-Weijnen CF, Geelhoed-Duijvestijn PH, Kanters TA. A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands. BMJ Open. 2018;8:e019864. doi:10.1136/bmjopen-2017-019864
   PubMed Web of Science ®Google Scholar
• Smith-Palmer J, Bae JP, Boye KS, Norrbacka K, Hunt B, Valentine WJ. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. Clinicoecon Outcomes Res. 2016;8:559–571. doi:10.2147/CEOR.S114699
   PubMed Web of Science ®Google Scholar
• Pathak V, Pathak NM, O’Neill CL, Guduric-Fuchs J, Medina RJ. Therapies for type 1 diabetes: current scenario and future perspectives. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419844521. doi:10.1177/1179551419844521
   Web of Science ®Google Scholar
• van Eeghen S, Krul-Poel Y, Linger-Wever S, Stam F, Simsek S. Evaluating glycaemic control of patients with type 1 diabetes mellitus in a Dutch hospital: a cross-sectional real-world database study using electronic medical records. Abstract presented at Annual Dutch Diabetes Research Meeting; 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645912/pdf/12467_2020_Article_611.pdf/?tool=EBI. Accessed August 24, 2022.
   Google Scholar
• Serné E, Mourits P, van Strien M. Nationale diabetes registratie: voor een toekomstbestendige en persoonsgerichte diabeteszorg in Nederland [National Diabetes Registry: For future-proof and person-oriented diabetes care in the Netherlands]. Nederlands Tijdschrift voor Diabetologie. 2020;18(2):27–31. doi:10.1007/s12467-020-0131-2
   Google Scholar
• National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management – NICE guideline [NG17] 2015; 2022. Available from: https://www.nice.org.uk/guidance/ng17/chapter/1-Recommendations#blood-glucose-management-2. Accessed August 24, 2022.
   Google Scholar
• Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther. 2007;29(8):1607–1619. doi:10.1016/j.clinthera.2007.08.020
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycemia in type 1 diabetes mellitus. Endocrinol Metab Clin North Am. 2010;39(3):641–654. doi:10.1016/j.ecl.2010.05.003
   PubMed Web of Science ®Google Scholar
• Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States. Adv Ther. 2020;37(2):869–882. doi:10.1007/s12325-019-01199-8
   PubMed Web of Science ®Google Scholar
• Hellgren M, Svensson AM, Franzén S, et al. The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: a health economic modelling analysis based on nationwide data. Diabetes Obes Metab. 2021;23(7):1604–1613. doi:10.1111/dom.14376
   PubMed Web of Science ®Google Scholar